MARKET

AKCA

Akcea
AKCA
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
41.41
4.392
3.850
1,846,353,471.47
News
Financial
Releases
Corp Actions
Analysis
Profile
Pfizer launches Phase 2b vupanorsen study in patients with elevated cholesterol level
Pfizer (PFE) has initiated a Phase 2b study of vupanorsen (AKCEA-ANGPTL3-L) in statin-treated patients with elevated non-high-density lipoprotein cholesterol (non-HDL-C) and triglycerides (TGs), says Ionis Pharmaceuticals (IONS) and its subsidiary
Seekingalpha · 11/04 04:40
Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the successful completion of its transaction to acquire 100% ownership of Akcea Therapeutics, Inc. (NASDAQ: AKCA). The combination of Ionis and Akcea accelerates the next phase of Ionis' growth and positions it to better deliver more medicines to patients while maximizing value to all stakeholders. Under the terms of the definitive agreement, Akcea shareholders will receive $18.15 in cash for each share of Akcea common stock. As a result of the completion of the transaction, Akcea has become a wholly owned subsidiary of Ionis, and the common stock of Akcea will cease to trade on NASDAQ and be delisted.
PR Newswire · 10/12 14:00
STOCKHOLDER ALERT: Monteverde & Associates Continues its Investigation into the Following Merger
NEW YORK, NY / ACCESSWIRE / September 23, 2020 / Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating: * Akcea Therapeutics, Inc.
ACCESSWIRE · 09/23 18:35
STOCKHOLDER ALERT: Monteverde & Associates Reminds Shareholders of its Continuing Investigation Regarding the Merger
NEW YORK, NY / ACCESSWIRE / September 20, 2020 / Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating: * Akcea Therapeutics, Inc.
ACCESSWIRE · 09/21 01:00
Akcea's Waylivra OK'd in England for ultra-rare inherited disorder
Akcea Therapeutics (AKCA), majority-owned affiliate of Ionis Pharmaceuticals (IONS) announces that the National Institute for Health and Care Excellence has issued a positive Final Evaluation Document for WAYLIVRA (volanesorsen) for the
Seekingalpha · 09/18 09:46
Akcea's Waylivra secures NICE recommendation for ultra-rare inherited disorder
Akcea Therapeutics (AKCA), majority-owned affiliate of Ionis Pharmaceuticals (IONS) announces that the National Institute for Health and Care Excellence ((NICE)) has issued a positive Final Evaluation Document for WAYLIVRA (volanesorsen) for
Seekingalpha · 09/18 09:46
WAYLIVRA® (volanesorsen), the First and Only Therapy for FCS, an Ultra-Rare and Life-Threatening Condition, to Be Available on the NHS in England
Business Wire · 09/18 08:00
MERGER ALERT – AKCA, RST, and BLDR: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
NEW YORK, NY / ACCESSWIRE / September 3, 2020 / The following statement is being issued by Levi & Korsinsky, LLP:Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following publicly-traded companies.
ACCESSWIRE · 09/03 17:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AKCA. Analyze the recent business situations of Akcea through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AKCA stock price target is 28.50 with a high estimate of 41.00 and a low estimate of 16.00.
EPS
Institutional Holdings
Institutions: 114
Institutional Holdings: 23.78M
% Owned: 23.41%
Shares Outstanding: 101.62M
TypeInstitutionsShares
Increased
37
1.59M
New
30
-35.70K
Decreased
18
2.41M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.23%
Pharmaceuticals & Medical Research
+1.71%
Key Executives
Chairman/Director
B. Lynne Parshall
Chief Executive Officer/Director
Damien McDevitt
Chief Financial Officer
Michael Price
Chief Operating Officer
Alex Howarth
Chief Human Resource Officer/Senior Vice President
Carla Poulson
Chief Compliance Officer
Tracy Berns
Other
Louis O Dea
General Counsel
Joshua Patterson
Other
William Andrews
Other
Kyle Jenne
Independent Director
Edward Fitzgerald
Independent Director
Christopher Gabrieli
Independent Director
Elaine Hochberg
Independent Director
Joseph Klein
Independent Director
Richard Moscicki
Independent Director
Amber Salzman
Independent Director
Sandford Smith
Independent Director
Michael Yang
Independent Director
Barbara Yanni
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now

Webull offers kinds of Akcea stock information, including NASDAQ:AKCA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKCA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AKCA stock methods without spending real money on the virtual paper trading platform.